Recipharm bolsters development business with new appointments in the US and Europe
CDMO appoints Anders Högdin and Aaron Small to lead the growth of its pharmaceutical development services business in the US and Europe.
Recipharm has appointed Anders Högdin and Aaron Small to lead the growth of its pharmaceutical development services business in the US and Europe.
Since forming in Sweden in 1995, Recipharm has experienced strong year-on-year growth and is now operating from 20+ sites across 10 countries. In addition to its manufacturing services offering, Recipharm delivers pharmaceutical development services from the early discovery phase to supply of clinical trial materials from facilities in Sweden, Italy, France, Israel and the US. Parallel to these new appointments, Recipharm has strengthened the respective sales team to create focus on customer management and new business opportunities.
Based in Stockholm, Sweden, Anders Högdin will head the business development and sales team within development services in Europe. Anders has a MSc in chemistry and a PhD in organic chemistry from Uppsala University. Before joining Recipharm in 2015, he was employed at Syntagon, APL and OnTarget Chemistry in various roles.
Focused on driving the growth of the Recipharm’s North American business, Aaron Small will work in close contact with the Recipharm facility in Research Triangle Park, North Carolina. Aaron has a BSc in marketing and a Master of Business Administration and has been part of Recipharm’s business management function since 2012.
Commenting on the appointments, Carl-Johan Spak, Executive Vice President, Global Technologies said: “Over the past year, Recipharm’s development business has continued to expand, with the integration of new facilities, technologies and capabilities. The new North American sales organisation will be extremely important for Recipharm as it will enable the company to attract US customers to its extensive network of development and manufacturing facilities outside of the US”.
“We are very pleased to have such skilled, ambitious and enthusiastic professionals like Anders and Aaron to lead these two sales teams. Their contributions will be extremely valuable in the development of our business in offering new and existing customers access to our world class contract development and manufacturing services.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance